Cargando…

Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)

INTRODUCTION: The optimal treatment for extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae bloodstream infections has yet to be defined. Retrospective studies have shown conflicting results, with most data suggesting the non-inferiority of beta-lactam–beta-lactamase inhibitor combinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bitterman, Roni, Koppel, Fidi, Mussini, Cristina, Geffen, Yuval, Chowers, Michal, Rahav, Galia, Nesher, Lior, Ben-Ami, Ronen, Turjeman, Adi, Huberman Samuel, Maayan, Cheng, Matthew P, Lee, Todd C, Leibovici, Leonard, Yahav, Dafna, Paul, Mical
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Infectious Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871690/ https://www.ncbi.nlm.nih.gov/pubmed/33558347 http://dx.doi.org/10.1136/bmjopen-2020-040210

Ejemplares similares

Duration of antibiotic treatment for Gram-negative bacteremia – Systematic review and individual participant data (IPD) meta-analysis
por: Turjeman, Adi, et al.
Publicado: (2022)

Risk factors for functional decline among survivors of Gram-negative bloodstream infection: A prospective cohort study
por: Turjeman, Adi, et al.
Publicado: (2021)

Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis
por: Daitch, Vered, et al.
Publicado: (2022)

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
por: Dickstein, Yaakov, et al.
Publicado: (2016)

External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA
por: Paul, Mical, et al.
Publicado: (2015)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Predicting In-Hospital Antibiotic Use in the Medical Department: Derivation and Validation Study
por: Poran, Itamar, et al.
Publicado: (2022)

A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection
por: Howard-Anderson, Jessica, et al.
Publicado: (2022)

Comment on Huang et al. Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection: A Meta-Analysis. J. Clin. Med. 2022, 11, 3239
por: Daitch, Vered, et al.
Publicado: (2022)

The association of vancomycin trough levels with outcomes among patients with methicillin-resistant Staphylococcus aureus (MRSA) infections: Retrospective cohort study
por: Yahav, Dafna, et al.
Publicado: (2019)

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs
por: Barber, Katie E., et al.
Publicado: (2016)

Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
por: Daitch, Vered, et al.
Publicado: (2021)

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem
por: Cannon, John M., et al.
Publicado: (2017)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group
por: Tiseo, Giusy, et al.
Publicado: (2021)

A systematic review assessing the under-representation of elderly adults in COVID-19 trials
por: Prendki, Virginie, et al.
Publicado: (2020)

Oral iron supplements for children in malaria‐endemic areas
por: Neuberger, Ami, et al.
Publicado: (2016)

Third generation cephalosporins and piperacillin/tazobactam have distinct impacts on the microbiota of critically ill patients
por: Gamage, Hasinika K. A. H., et al.
Publicado: (2021)

Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial
por: Paul, Mical, et al.
Publicado: (2015)

Is shorter always better? The pros and cons of treating Gram-negative bloodstream infections with 7 days of antibiotics
por: Yahav, Dafna, et al.
Publicado: (2022)

Optimizing patient recruitment into clinical trials of antimicrobial-resistant pathogens
por: Paul, Mical, et al.
Publicado: (2023)

Comparison of Rates of Acute Kidney Injury with Vancomycin/Piperacillin-Tazobactam vs. Vancomycin/Meropenem Combination Therapy
por: Pernia, Sonia, et al.
Publicado: (2017)

Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation
por: Nasr, Dayana, et al.
Publicado: (2022)

2746. Assessment of in vitro synergy between Piperacillin-Tazobactam-Meropenem and Imipenem-Meropenem against OXA-48 Producing Klebsiella pneumoniae Using Time-Kill Assays
por: Demir, Mervenur, et al.
Publicado: (2023)

Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: A case report
por: Song, Gao, et al.
Publicado: (2022)

2576. Piperacillin-Tazobactam or Cefepime for Treatment of Third Generation Cephalosporin Resistant Pneumonia in Intensive Care Unit Patients
por: DeLaurentis, Clare, et al.
Publicado: (2023)

Antimicrobial drugs for treating cholera
por: Leibovici‐Weissman, Ya'ara, et al.
Publicado: (2014)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
por: Scharf, Christina, et al.
Publicado: (2020)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

1292. Evaluation of Synergy with Piperacillin/Tazobactam plus Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae and Enterobacter cloacae Using ETEST
por: Ashcraft, Deborah S, et al.
Publicado: (2021)

Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible Escherichia coli: A Missed Opportunity for De-Escalation of Therapy
por: Carlisle, Leah, et al.
Publicado: (2018)

Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates
por: Ontong, Julalak C., et al.
Publicado: (2021)

Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae
por: Kresken, Michael, et al.
Publicado: (2021)

Piperacillin/tazobactam-resistant, cephalosporin-susceptible Escherichia coli bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types
por: Edwards, Thomas, et al.
Publicado: (2022)

Piperacillin-Tazobactam Versus Anti-Pseudomonal Cephalosporins and Renal and Neurologic Outcomes in Critically Ill Adults: A Secondary Analysis of the SMART Trial
por: Qian, Edward T., et al.
Publicado: (2023)

1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
por: Aslan, Abdullah Tarik, et al.
Publicado: (2018)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Correction: Synergistic antibacterial effects of colistin in combination with aminoglycoside, carbapenems, cephalosporins, fluoroquinolones, tetracyclines, fosfomycin, and piperacillin on multidrug resistant Klebsiella pneumoniae isolates
Publicado: (2021)

Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study
por: Joly-Guillou, Marie-Laure, et al.
Publicado: (2010)

486 Meropenem and Piperacillin-tazobactam have Comparable Outcomes in Treatment of Bloodstream Infections Caused by Extended Spectrum Beta-lactamase Producing E.coli and Klebsiellae
por: Harris, Patrick, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6fig3lof87qte29grm9n3mjltp